{"id":"bendamustine-eam","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Bendamustine functions as a bifunctional alkylating agent that binds to DNA and causes interstrand cross-links, leading to cell death. The EAM regimen combines bendamustine with etoposide (a topoisomerase II inhibitor) and cytarabine (a nucleoside analog), creating a multi-modal chemotherapy approach. This combination is typically used as a conditioning regimen prior to autologous stem cell transplantation in hematologic malignancies.","oneSentence":"Bendamustine is an alkylating agent that cross-links DNA to kill rapidly dividing cancer cells, often used in combination with other chemotherapy agents (EAM regimen includes etoposide and cytarabine).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:22:56.344Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Conditioning regimen prior to autologous hematopoietic stem cell transplantation in lymphomas and other hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT01296256","phase":"PHASE2","title":"Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2011-05","conditions":"Bendamustine, Conditioning Therapy, Autologous Stem Cell Transplant","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Bendamustine-EAM","genericName":"Bendamustine-EAM","companyName":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","companyId":"grupo-espa-ol-de-linfomas-y-transplante-aut-logo-de-m-dula-sea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bendamustine is an alkylating agent that cross-links DNA to kill rapidly dividing cancer cells, often used in combination with other chemotherapy agents (EAM regimen includes etoposide and cytarabine). Used for Conditioning regimen prior to autologous hematopoietic stem cell transplantation in lymphomas and other hematologic malignancies.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}